Palvella Therapeutics (PVLA) is a pre-revenue clinical-stage biopharma. Under a liquidation lens as of March 31, 2026, recovery to equity is primarily driven by the cash and short-term investment position, which collectively total $261.9 million ($206.4M cash and cash equivalents plus $55.5M short-term investments in available-for-sale debt securities). At 100% and near-100% recovery respectively, these two positions constitute essentially all realizable asset value. Non-financial assets are negligible: prepaid and other current assets of $1.4M (modest haircut applicable), a right-of-use asset of $0.5M (zero liquidation value), and no tangible PP&E or inventory of consequence. Intangibles carried at zero on the balance sheet; QTORIN platform and pipeline IP have no assigned book value and receive a 0% recovery haircut under the lens by definition. Total reported assets are $263.8M, with $263.2M current. Against this, total liabilities stand at $31.4M, of which $9.1M is current. The most structurally significant liability is the royalty agreement liability to Ligand Pharmaceuticals, which is carried as a debt instrument and classified as noncurrent; the filing records non-cash interest expense of $2.0M in Q1 2026 against this instrument. The Ligand obligation also carries a $5.0M remaining milestone payment liability (future regulatory triggers) and tiered royalties of 8.0-9.8% on net product sales, neither of which extinguishes on liquidation. The derivative liability associated with Ligand milestone payments stands at $2.16M noncurrent. Contingent value right (CVR) derivative liability appears de minimis following the $2.0M CVR payout in January 2026. Operating lease liabilities total $0.6M ($0.2M current, $0.4M noncurrent), which would not extinguish on windup. Accumulated deficit is $151.2M. On a net liquidation basis: haircut assets approximate $261.9M (cash + investments at near-par) plus negligible other current assets, offset by $31.4M face-value liabilities including the Ligand royalty agreement liability (filing does not separately XBRL-tag the carrying value of the royalty agreement liability in TAG_CONTEXT, so the precise balance is not determinable from the tag set alone; it is disclosed in MD&A as a material obligation). The resulting estimated liquidation recovery to equity is substantially positive, reflecting the February 2026 equity raise of $215.8M net proceeds. Compared to the prior 10-K (December 31, 2025), the balance sheet has been materially strengthened: cash and investments increased by approximately $148M net in the quarter, entirely due to the February 2026 public equity offering. Operating cash burn was $10.9M for Q1 2026, annualizing to roughly $44M, implying approximately 5-6 years of runway at the current burn rate before the $261.9M cash and investment pool is exhausted, absent increased spend.
▼ Community Notes